Which adjuvant chemotherapy regimen would you recommend for a peri-menopausal woman with synchronous stage IA primary breast tumors, one that is ER+HER2+ and the second ER+HER2-?
Community PollStarted
What adjuvant endocrine therapy would you recommend for a peri-menopausal woman who will receive weekly paclitaxel/trastuzumab for synchronous stage IA primary ER+HER2+ and ER+HER2- breast cancers?
80 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Icahn School of Medicine at Mount Sinai
Answered on
I would treat the patient with paclitaxel 80mg/m2 x 12 weeks plus trastuzumab for a year (Tolaney et al., Clin Oncol 2019). The more difficult question is the optimal anti-estrogen therapy: tamoxifen (TAM), TAM + ovarian suppression (OS), or aromatase inhibitor (AI) + OS. This is because the SOFT an...
Join for free or sign in to see the full answer